Analyst Viewpoint
Advancements in cancer treatment and growth in understanding of the immune system's role in combating diseases are propelling the immunotherapy drugs market size. The market is witnessing a surge in research and development activities, leading to the introduction of innovative therapies. Key players in the pharmaceutical industry are focusing on expanding their immunotherapy portfolios to address various cancers and improve patient outcomes.
One notable trend in the immunotherapy drugs market landscape is the emergence of combination therapies, where different immunotherapeutic agents are used together or in conjunction with traditional treatments. This approach aims to enhance the overall effectiveness of immunotherapy and broaden its applicability across different cancer types.
Immunotherapy is a type of medical treatment that stimulates the body's immune system to fight diseases, including cancer. Immunotherapy drugs are designed to enhance or modify the immune system's response to target and eliminate abnormal cells. Immunotherapy is used to treat various cancers including melanoma, Non-small Cell Lung Cancer (NSCLC), and Head and Neck Squamous Cell Carcinoma (HNSCC). It targets the PD-1 protein in immune cells, allowing them to attack cancer cells more effectively. Immunotherapy is employed in the treatment of certain types of lymphoma and leukemia. It involves modifying a patient's own T cells to express a Chimeric Antigen Receptor (CAR) that targets cancer cells.
Traditional treatments often rely on a one-size-fits-all approach, which may not be effective for every patient. Immunotherapy, on the other hand, leverages the body's immune system to target specific abnormalities, offering a more tailored and effective treatment.
Biotechnological advancements have played a pivotal role in the development of immunotherapeutic drugs, enabling the creation of novel therapies that can selectively target cancer cells, autoimmune disorders, and other diseases. Breakthroughs in genetic sequencing, biomarker identification, and understanding the immune system's complexities have paved the way for personalized immunotherapies. As a result, pharmaceutical companies are increasingly investing in research and development to create innovative drugs that can be customized based on an individual's genetic makeup, ensuring better treatment outcomes. The integration of biomarkers in immunotherapy research has facilitated the identification of patients who are more likely to respond positively to specific treatments.
According to the latest immunotherapy drugs market trends, the monoclonal antibodies drug type segment held largest share in 2022. Monoclonal antibodies are laboratory-produced molecules designed to mimic the immune system's ability to fight off harmful pathogens, including cancer cells. They can be used for various therapeutic purposes such as cancer treatment.
These mAbs block specific proteins on immune cells or cancer cells, preventing them from inhibiting the immune system's ability to attack cancer. Examples include pembrolizumab, nivolumab, and ipilimumab. Some mAbs are designed to bind directly to cancer cells, marking them for destruction by the immune system or delivering signals that trigger cell death.
According to the latest immunotherapy drugs market analysis, the cancer therapy area segment held largest share in 2022. Immunotherapy has become a prominent and rapidly growing area within cancer therapy. Immunotherapy, which includes treatments like immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, has shown promising results in various types of cancers by harnessing the body's immune system to target and eliminate cancer cells.
Immunotherapy has demonstrated notable success in treating certain cancers, with durable responses and improved overall survival rates in some cases. Several immunotherapy drugs, such as pembrolizumab, nivolumab, and ipilimumab, have gained approval for treating various cancers, leading to increased adoption in clinical practice. Continuous research and development efforts in the field of immunotherapy have resulted in the identification of new targets and the development of novel therapeutic approaches, expanding the range of treatable cancers.
According to the latest immunotherapy drugs market research, the retail pharmacies distribution channel segment accounted for major share in 2022. The choice of distribution channel can depend on several factors, including the nature of the drug, patient access, and regulatory considerations. Retail pharmacies may be more suitable for certain types of immunotherapy drugs, especially those that can be administered or self-administered on an outpatient basis.
North America accounted for the largest immunotherapy drugs industry share in 2022. The U.S. is a significant contributor to the industry in the region, with a well-established healthcare system and a high prevalence of cancer. Rise in investment in clinical trials and research activities is propelling the immunotherapy drugs market dynamics in North America. Regulatory agencies such as the FDA play a crucial role in approving and fast-tracking immunotherapy drugs.
Growth in cancer incidence, improvement in healthcare infrastructure, and increase in investment in research and development are driving the immunotherapy drugs market expansion in Asia Pacific. China, Japan, and India are major markets for immunotherapy drugs in the region. Access to immunotherapies may vary across countries due to economic disparities.
Immunotherapy drug manufacturers are adopting various strategies, such as new product launches, mergers, partnerships, and collaborations, to strengthen their position Bristol Myers Squibb, Merck KGaA, Inc., F. Hoffmann-La Roche AG, Novartis AG, AstraZeneca, Pfizer, Amgen, Gilead Sciences, Eli Lilly and Company, and Regeneron Pharmaceuticals Inc. are the prominent players in this market.
Each of these companies has been profiled in the immunotherapy drugs market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 126.4 Bn |
| Market Forecast (Value) in 2031 | More than US$ 237.4 Bn |
| Growth Rate (CAGR) | 7.1% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape | Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials |
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 126.4 Bn in 2022
It is projected to reach more than US$ 237.4 Bn by the end of 2031
It is anticipated to be 7.1% from 2023 to 2031
Advancements in biotechnology and personalized medicines
The monoclonal antibodies drug type segment accounted for major share in 2022
North America is expected to account for major share during the forecast period
Bristol Myers Squibb, Merck KGaA, Inc., F. Hoffmann-La Roche AG, Novartis AG, AstraZeneca, Pfizer, Amgen, Gilead Sciences, Eli Lilly and Company, and Regeneron Pharmaceuticals Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Immunotherapy Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Global Immunotherapy Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. COVID-19 Impact Analysis
6. Global Immunotherapy Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Immunomodulators
6.3.3. Cell Therapy
6.3.4. Others (Vaccines, etc.)
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Immunotherapy Drugs Market Analysis and Forecast, by Therapy Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapy Area, 2017–2031
7.3.1. Cancer
7.3.2. Autoimmune Diseases
7.3.3. Infectious Diseases
7.3.4. Others
7.4. Market Attractiveness Analysis, by Therapy Area
8. Global Immunotherapy Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Online Pharmacies
8.3.3. Hospital Pharmacies
9. Global Immunotherapy Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Immunotherapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Immunomodulators
10.2.3. Cell Therapy
10.2.4. Others (Vaccines, etc.)
10.3. Market Value Forecast, by Therapy Area, 2017–2031
10.3.1. Cancer
10.3.2. Autoimmune Diseases
10.3.3. Infectious Diseases
10.3.4. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Online Pharmacies
10.4.3. Hospital Pharmacies
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Therapy Area
10.5.3. By Distribution Channel
10.5.4. By Country
11. Europe Immunotherapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Immunomodulators
11.2.3. Cell Therapy
11.2.4. Others (Vaccines, etc.)
11.3. Market Value Forecast, by Therapy Area, 2017–2031
11.3.1. Cancer
11.3.2. Autoimmune Diseases
11.3.3. Infectious Diseases
11.3.4. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Online Pharmacies
11.4.3. Hospital Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Therapy Area
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Immunomodulators
12.2.3. Cell Therapy
12.2.4. Others (Vaccines, etc.)
12.3. Market Value Forecast, by Therapy Area, 2017–2031
12.3.1. Cancer
12.3.2. Autoimmune Diseases
12.3.3. Infectious Diseases
12.3.4. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Online Pharmacies
12.4.3. Hospital Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Therapy Area
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Immunotherapy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Immunomodulators
13.2.3. Cell Therapy
13.2.4. Others (Vaccines, etc.)
13.3. Market Value Forecast, by Therapy Area, 2017–2031
13.3.1. Cancer
13.3.2. Autoimmune Diseases
13.3.3. Infectious Diseases
13.3.4. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Online Pharmacies
13.4.3. Hospital Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Therapy Area
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Immunomodulators
14.2.3. Cell Therapy
14.2.4. Others (Vaccines, etc.)
14.3. Market Value Forecast, by Therapy Area, 2017–2031
14.3.1. Cancer
14.3.2. Autoimmune Diseases
14.3.3. Infectious Diseases
14.3.4. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Online Pharmacies
14.4.3. Hospital Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Therapy Area
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Immunotherapy Drugs Market, Company Share Analysis (2022)
15.2. Company Profiles
15.2.1. Bristol Myers Squibb
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Merck KGaA, Inc.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Novartis AG
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Pfizer
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Amgen
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Regeneron Pharmaceuticals Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. F. Hoffmann-La Roche AG
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. Eli Lilly and Company
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
List of Tables
Table 01: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 02: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 03: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 07: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 08: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 11: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 12: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 15: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 16: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 19: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 20: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
Table 23: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Therapy Area, 2017-2031
Table 24: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Immunotherapy Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Immunotherapy Drugs Market Value Share, by Region, 2022
Figure 03: Global Immunotherapy Drugs Market Value Share, by Drug Type, 2022
Figure 04: Global Immunotherapy Drugs Market Value Share, by Therapy Area, 2022
Figure 05: Global Immunotherapy Drugs Market Value Share, by Distribution Channel, 2022
Figure 06: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2022 and 2031
Figure 07: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2022
Figure 08: Global Immunotherapy Drugs Market Value Share Analysis, by Drug Type, 2031
Figure 09: Global Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 10: Global Immunotherapy Drugs Market Value (US$ Mn), by Monoclonal Antibodies, 2017‒2031
Figure 11: Global Immunotherapy Drugs Market Value Share Analysis, by Monoclonal Antibodies, 2022 and 2031
Figure 12: Global Immunotherapy Drugs Market Value (US$ Mn), by Immunomodulators, 2017‒2031
Figure 13: Global Immunotherapy Drugs Market Value Share Analysis, by Immunomodulators, 2022 and 2031
Figure 14: Global Immunotherapy Drugs Market Value (US$ Mn), by Cell Therapy, 2017‒2031
Figure 15: Global Immunotherapy Drugs Market Value Share Analysis, by Cell Therapy, 2022 and 2031
Figure 16: Global Immunotherapy Drugs Market Value (US$ Mn), by Others, 2017‒2031
Figure 17: Global Immunotherapy Drugs Market Value Share Analysis, by Others, 2022 and 2031
Figure 18: Global Immunotherapy Drugs Market Value Share Analysis, by Therapy Area, 2022 and 2031
Figure 19: Global Immunotherapy Drugs Market Value Share Analysis, by Therapy Area, 2022
Figure 20: Global Immunotherapy Drugs Market Value Analysis, by Therapy Area, 2031
Figure 21: Global Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 22: Global Immunotherapy Drugs Market Value (US$ Mn), by Cancer, 2017‒2031
Figure 23: Global Immunotherapy Drugs Market Value Share Analysis, by Cancer, 2022 and 2031
Figure 24: Global Immunotherapy Drugs Market Value (US$ Mn), by Autoimmune Diseases, 2017‒2031
Figure 24: Global Immunotherapy Drugs Market Value Share Analysis, by Autoimmune Diseases, 2022 and 2031
Figure 25: Global Immunotherapy Drugs Market Value (US$ Mn), by Autoimmune Diseases, 2017‒2031
Figure 25: Global Immunotherapy Drugs Market Value Share Analysis, by Autoimmune Diseases, 2022 and 2031
Figure 26: Global Immunotherapy Drugs Market Value (US$ Mn), by Others, 2017‒2031
Figure 27: Global Immunotherapy Drugs Market Value Share Analysis, by Others, 2022 and 2031
Figure 28: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 29: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2022
Figure 30: Global Immunotherapy Drugs Market Value Share Analysis, by Distribution Channel, 2031
Figure 31: Global Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 32: Global Immunotherapy Drugs Market Value (US$ Mn), by Retail Pharmacies, 2017‒2031
Figure 33: Global Immunotherapy Drugs Market Value Share Analysis, by Retail Pharmacies, 2022 and 2031
Figure 34: Global Immunotherapy Drugs Market Value (US$ Mn), by Online Pharmacies, 2017‒2031
Figure 35: Global Immunotherapy Drugs Market Value Share Analysis, by Online Pharmacies, 2022 and 2031
Figure 36: Global Immunotherapy Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2017‒2031
Figure 36: Global Immunotherapy Drugs Market Value Share Analysis, by Hospital Pharmacies, 2022 and 2031
Figure 37: Global Immunotherapy Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 38: Global Immunotherapy Drugs Market Value Share Analysis, by Region, 2022
Figure 39: Global Immunotherapy Drugs Market Value Analysis, by Region, 2031
Figure 40: Global Immunotherapy Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 41: North America Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 42: North America Immunotherapy Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 43: North America Immunotherapy Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 44: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031
Figure 45: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022
Figure 46: North America Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 47: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031
Figure 48: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022
Figure 49: North America Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 50: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: North America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022
Figure 52: North America Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 53: Europe Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 54: Europe Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 55: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031
Figure 57: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022
Figure 58: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 59: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031
Figure 60: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022
Figure 61: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 62: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031
Figure 63: Europe Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022
Figure 64: Europe Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 65: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 66: Asia Pacific Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 67: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031
Figure 69: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022
Figure 70: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 71: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031
Figure 72: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022
Figure 73: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 74: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031
Figure 75: Asia Pacific Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022
Figure 76: Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 77: Latin America Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 78: Latin America Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 79: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 80: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031
Figure 81: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022
Figure 82: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 83: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031
Figure 84: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022
Figure 85: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 86: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031
Figure 87: Latin America Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022
Figure 88: Latin America Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 89 Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 90: Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 91: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 92: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022 and 2031
Figure 93: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Drug Type, 2022
Figure 94: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 95: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022 and 2031
Figure 96: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Therapy Area, 2023–2031
Figure 97: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Therapy Area, 2022
Figure 98: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022 and 2031
Figure 99: Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 100: Middle East & Africa Immunotherapy Drugs Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Immunotherapy Drugs Market
*86 figures and 60 tables includes